Repligen Corp RGEN
We take great care to ensure that the data presented and summarized in this overview for REPLIGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGEN
View all-
Black Rock Inc. New York, NY7.77MShares$1.34 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$877 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.57MShares$614 Million0.08% of portfolio
-
State Street Corp Boston, MA1.76MShares$302 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C31.46MShares$252 Million0.31% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.43MShares$246 Million0.77% of portfolio
-
Invesco Ltd. Atlanta, GA1.24MShares$214 Million0.05% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.15MShares$199 Million3.81% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI1.12MShares$193 Million0.32% of portfolio
-
Wellington Management Group LLP Boston, MA1.11MShares$191 Million0.04% of portfolio
Latest Institutional Activity in RGEN
Top Purchases
Top Sells
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Transactions at RGEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Ralf Kuriyel Senior VP, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
534
-2.2%
|
$87,042
$163.34 P/Share
|
May 14
2024
|
Christine Gebski |
SELL
Payment of exercise price or tax liability
|
Direct |
334
-1.2%
|
$54,442
$163.34 P/Share
|
Apr 02
2024
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
444
-2.11%
|
$80,808
$182.95 P/Share
|
Mar 18
2024
|
Anthony Hunt Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
2,000
-1.08%
|
-
|
Mar 18
2024
|
Margaret Pax |
BUY
Grant, award, or other acquisition
|
Direct |
92
+50.0%
|
-
|
Mar 11
2024
|
Ralf Kuriyel Senior VP, R&D |
SELL
Open market or private sale
|
Direct |
3,517
-12.66%
|
$678,781
$193.73 P/Share
|
Mar 11
2024
|
Ralf Kuriyel Senior VP, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,271
+4.38%
|
$109,306
$86.1 P/Share
|
Mar 08
2024
|
Anthony Hunt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,707
-1.07%
|
$3,324,693
$199.02 P/Share
|
Mar 08
2024
|
Anthony Hunt Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1
+0.0%
|
$16
$16.55 P/Share
|
Mar 07
2024
|
Ralf Kuriyel Senior VP, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
386
-1.44%
|
$75,270
$195.72 P/Share
|
Mar 07
2024
|
Anthony Hunt Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,867
-1.4%
|
$559,065
$195.72 P/Share
|
Mar 07
2024
|
Christine Gebski |
SELL
Payment of exercise price or tax liability
|
Direct |
386
-1.37%
|
$75,270
$195.72 P/Share
|
Mar 07
2024
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,206
-5.42%
|
$235,170
$195.72 P/Share
|
Mar 05
2024
|
Anthony Hunt Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,275
-3.43%
|
$1,418,625
$195.52 P/Share
|
Mar 05
2024
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22
-0.1%
|
$4,290
$195.52 P/Share
|
Mar 04
2024
|
Anthony Hunt Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,111
-0.52%
|
$214,423
$193.99 P/Share
|
Mar 04
2024
|
James Bylund Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
197
-0.88%
|
$38,021
$193.99 P/Share
|
Mar 04
2024
|
Christine Gebski |
SELL
Payment of exercise price or tax liability
|
Direct |
592
-1.03%
|
$114,256
$193.35 P/Share
|
Mar 04
2024
|
Ralf Kuriyel Senior VP, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
135
-0.5%
|
$26,055
$193.99 P/Share
|
Mar 01
2024
|
James Bylund Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50
+0.22%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 64.5K shares |
---|---|
Exercise of conversion of derivative security | 14.2K shares |
Payment of exercise price or tax liability | 20.5K shares |
---|---|
Bona fide gift | 3K shares |
Open market or private sale | 30.2K shares |